MarketBeat reported a Moderate Buy consensus rating for Genelux, while Benchmark reissued a speculative buy rating, and an insider sold shares.
1 report, 1 independent
Updated Sep 1
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
MarketBeat reported a Moderate Buy consensus rating for Genelux, while Benchmark reissued a speculative buy rating, and an insider sold shares.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Genelux Corporation
biopharmaceutical company
Nothing else this week.
-
MarketBeat
American personal finance blog
-
Benchmark
venture capital firm
Related events
- MarketBeat reported the stock's average rating as Benchmark and Jefferies reiterated buy ratings for Bright Minds Biosciences Inc.
- MarketBeat is reporting on consensus ratings for Aehr Test Systems, a company whose stock trades on the Nasdaq exchange.
- MarketBeat reported the stock consensus rating for NextPlat on November 1, 2026.
- MarketBeat reported consensus ratings and target prices for Deep Fission Inc., which received a strong-buy rating from Benchmark.
- MarketBeat reported the stock consensus rating for Stabilis Solutions.